{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blinded+%28placebo%29&page=75", "query": { "intervention": "Blinded (placebo)", "page": 75 }, "page_size": 10 }, "pagination": { "page": 75, "page_size": 10, "total_count": 2216, "total_pages": 222, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blinded+%28placebo%29&page=76&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blinded+%28placebo%29&page=74&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-30T15:20:54.540Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00890162", "title": "A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anaphylaxis", "Hypotension", "Bronchospasm", "Angioedema" ], "interventions": [ { "name": "Epinephrine", "type": "DRUG" }, { "name": "Omalizumab (Xolair)", "type": "DRUG" }, { "name": "Placebos", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 16, "start_date": "2009-04-27", "completion_date": "2019-05-31", "has_results": true, "last_update_posted_date": "2019-07-01", "last_synced_at": "2026-10-30T15:20:54.540Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00890162" }, { "nct_id": "NCT00299546", "title": "A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With Active Rheumatoid Arthritis Previously Treated With Biologic Anti-TNFa Agent(s)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arthritis, Rheumatoid" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Golimumab 50 mg", "type": "BIOLOGICAL" }, { "name": "Golimumab 100 mg", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Centocor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 461, "start_date": "2006-02", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2014-02-27", "last_synced_at": "2026-10-30T15:20:54.540Z", "location_count": 40, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 37 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Paradise Valley", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00299546" }, { "nct_id": "NCT04186403", "title": "Evaluating the Safety and Tolerability of Brexpiprazole in the Treatment of Adults With Borderline Personality Disorder (BPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Borderline Personality Disorder" ], "interventions": [ { "name": "Brexpiprazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 201, "start_date": "2020-01-13", "completion_date": "2021-09-22", "has_results": true, "last_update_posted_date": "2024-10-03", "last_synced_at": "2026-10-30T15:20:54.540Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04186403" }, { "nct_id": "NCT04992546", "title": "Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "PRN473 (SAR444727)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Principia Biopharma, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 39, "start_date": "2021-08-13", "completion_date": "2022-12-28", "has_results": true, "last_update_posted_date": "2025-09-10", "last_synced_at": "2026-10-30T15:20:54.540Z", "location_count": 9, "location_summary": "Long Beach, California • Los Angeles, California • Miami, Florida + 6 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Sweetwater", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04992546" }, { "nct_id": "NCT04972227", "title": "Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "CY6463", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tisento Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 48, "start_date": "2021-09-10", "completion_date": "2022-04-18", "has_results": false, "last_update_posted_date": "2024-08-13", "last_synced_at": "2026-10-30T15:20:54.540Z", "location_count": 2, "location_summary": "Long Beach, California • Marlton, New Jersey", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Marlton", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04972227" }, { "nct_id": "NCT04612803", "title": "Antihistamines in the Treatment of Irritable Bowel Syndrome With Diarrhea", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Irritable Bowel Syndrome", "Dermatographism", "Post-prandial Diarrhea" ], "interventions": [ { "name": "Antihistamine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2020-02-01", "completion_date": "2026-08-31", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-10-30T15:20:54.540Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04612803" }, { "nct_id": "NCT06613685", "title": "Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "lepetegravir", "type": "DRUG" }, { "name": "lenacapavir pacfosacil", "type": "DRUG" }, { "name": "Bictegravir/emtricitabine/tenofovir alafenamide", "type": "DRUG" }, { "name": "lepetegravir/lenacapavir pacfosacil FDC", "type": "DRUG" }, { "name": "Placebo to Match BVY", "type": "DRUG" }, { "name": "Placebo to Match GS1720/GS-4182 FDC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 73, "start_date": "2024-10-21", "completion_date": "2026-03-16", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-10-30T15:20:54.540Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Torrance, California • West Hollywood, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Torrance", "state": "California" }, { "city": "West Hollywood", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "DeLand", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06613685" }, { "nct_id": "NCT00542009", "title": "A Trial In Diabetic Patients To Assess Effect Of CE-326,597 On Glucose Control And Body Weight", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Weight Management", "Treatment Of Obesity" ], "interventions": [ { "name": "CE-326,597 100 mg QD", "type": "DRUG" }, { "name": "CE-326,597 50 mg QD", "type": "DRUG" }, { "name": "CE-326,597 25 mg QD", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "CE-326,597 5mg QD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 252, "start_date": "2007-12", "completion_date": "2008-11", "has_results": false, "last_update_posted_date": "2012-11-07", "last_synced_at": "2026-10-30T15:20:54.540Z", "location_count": 30, "location_summary": "Phoenix, Arizona • Fresno, California • National City, California + 23 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "National City", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00542009" }, { "nct_id": "NCT06847698", "title": "Single Ascending Dose and Multiple Ascending Dose Study of AVR-48", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Safety Issues", "Tolerability", "Pharmacokinetics", "Pharmacodynamics" ], "interventions": [ { "name": "AVR-48", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AyuVis Research, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 48, "start_date": "2025-06", "completion_date": "2025-11", "has_results": false, "last_update_posted_date": "2025-04-06", "last_synced_at": "2026-10-30T15:20:54.540Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06847698" }, { "nct_id": "NCT02236598", "title": "The Effects of Potassium on Glucose Metabolism in African Americans", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Borderline Hypokalemia" ], "interventions": [ { "name": "K+ supplement", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "ALL", "summary": "30 Years and older" }, "enrollment_count": 61, "start_date": "2015-01", "completion_date": "2016-02-29", "has_results": true, "last_update_posted_date": "2017-05-23", "last_synced_at": "2026-10-30T15:20:54.540Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02236598" } ] }